IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

John R, HESS et al.

Appl. No. 09/756,907

Filed: January 10, 2001

For: COMPOSITIONS FOR

TREATMENT OF

HEMORRHAGING WITH ACTIVATED FACTOR VLLA IN

COMBINATION WITH

FIBRINOGEN AND METHODS

OF USING SAME

Art Unit: 3614

Examiner: n/a

Atty. Docket No. 38644-170537

Customer No. 6339

26694

PATENT TRADEMARK OFFICE

RECEIVED

APR 0 2 2002

INFORMATION DISCLOSURE STATEMENT GROUP 3

Assistant Commissioner for Patents Washington, DC 20231

Sir:

This is an Information Disclosure Statement submitted under 37 C.F.R. § 1.97 within the time specified under 37 C.F.R. § 1.97(b), PTO-1449 and copies of references cited therein, listing references reported in the enclosed International Search Report English language family members noted therein.

In order to comply with applicant's duty of disclosure under 37 C.F.R. § 1.56, the U.S. Patent and Trademark Office is notified of the documents which are listed on the attached Form PTO-1449 and which the Examiner may deem relevant to patentability of the claims of the above-identified application. One copy of each of the listed documents is submitted herewith.

The present Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits, and therefore no Statement Under 37 C.F.R. § 1.97(e) or fee under 37

C.F.R. § 1.17(p) is required.

In view of the above, no further translation or statement of relevance is required, and as all

requirements of 37 C.F.R. § 1.97 and all official guide lines pertaining to Information Disclosure

Statements have been complied with, and it is therefore respectfully requested that the Examiner

consider the documents and make them of record.

REMARKS

In the unlikely event that the transmittal letter is separated from this document and the

Patent Office determines that an extension and/or other relief is required, applicant petitions for any

required relief including extensions of time and authorizes the Assistant Commissioner to charge

the cost of such petitions and/or other fees due in connection with the filing of this document to

Deposit Account No. 22-0261. However, the Assistant Commissioner is not authorized to charge

the cost of the issue fee to the Deposit Account.

Date: March 29, 2002

Respectfully submitted,

Thomas G. Wiseman

Registration No. 35,046

VENABLE

P.O. Box 34385

Washington, D.C. 20043-9998

Telephone: (202) 962-4800

Telex: (202) 962-8300

::ODMA\PCDOCS\DC2DOCS1\362455\1

2

Attorney Docket Number

38644-170537

		_		U.S. PATENT DOCUM	MENTS	
Examiner	Cite No.1	U.S. Patent Document Kind Code ²		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
Initials *	No.	Number (if kn		or ones becamen	MM-DD-YYYY	Figures Appear
		5,504,067	Α	Morrissey et al.	April 2, 1996	
	_	5,866,122	A	Turecck et al.	February 2, 1999	
<u> </u>			1			
					· · · · · · · · · · · · · · · · · · ·	
	ļ					
						.12
	-					CENT
						RE 201
						RECE, APR 0 2 200
	 					1911
						GRUU
	_	-				
	-		_			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Name of Patentee	Date of Publication of	Pages, Columns, Lines,		
		Office ³	Number ⁴	Kind Code ⁵ (if known)	or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T ₆
		EPO	97/29792		WIPO	08/21/97		
		ļ						
		<u> </u>			_			
		ļ						
		<u> </u>						
		1					- "	

Examiner Signature	Date Considered	

SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Sheet



EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a	plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

B. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are paged for respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of 2

Complete if Known				
Application Number	09/756,907			
Filing Date	January 10, 2001			
First Named Inventor	John R. HESS et al.			
Group Art Unit	3614			
Examiner Name	n/z			
Attorney Docket Number	38644-170537			

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS		
Examiner Initials *	Cite No.1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
		HEDNER U.: Treatment of patents with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.: THROMOSIS AND HAEMOSTASIS: vol. 82, no. 2, 1999: pages 531-539.		
		SCHMIDT M.L. ET AL.: Recombinant activated factor VII therapy for intracranial hemmrhage in hemophilia A patnets with inhibitors: american journal of hematology: vol 47, no. 1, 1994, pages 36-40.		
			2	
		CK, Sy v	Ö	
•		St. 84 OB		
		C.R.O		
		9		

Examiner Signature	Date Considered		
		· · · · · · · · · · · · · · · · · · ·	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

